Literature DB >> 2246771

Fragile Xq27.3 in female heterozygotes for the Martin-Bell syndrome.

T Webb1, P A Jacobs.   

Abstract

X inactivation studies have been carried out on lymphocytes from eight unrelated females heterozygous for the Martin-Bell syndrome. Four of these carriers were of normal IQ and four were mentally handicapped. When BrdU was used to differentiate between the active and inactive X chromosome an average of 55% of fra(X) were active in the retarded subjects, but only 27% were active in those of normal IQ. When 3H thymidine was used to differentiate between the active and inactive X chromosome, an average of 58% of mitoses from handicapped subjects and 33% of mitoses from normal subjects showed an active fra(X) in informative cells. These results are compared with previously published studies and it is concluded that the number of inactive fra(X) chromosomes calculated as a proportion of all cells scored is the same in mentally normal and mentally retarded subjects. However, the number of active fra(X) chromosomes is consistently higher in the retarded than in the normal females.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2246771      PMCID: PMC1017241          DOI: 10.1136/jmg.27.10.627

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  18 in total

Review 1.  X-chromosome inactivation and developmental patterns in mammals.

Authors:  M F Lyon
Journal:  Biol Rev Camb Philos Soc       Date:  1972-01

2.  The marker (X) syndrome: a cytogenetic and genetic analysis.

Authors:  S L Sherman; N E Morton; P A Jacobs; G Turner
Journal:  Ann Hum Genet       Date:  1984-01       Impact factor: 1.670

3.  X-linked mental retardation: a study of 7 families.

Authors:  P A Jacobs; T W Glover; M Mayer; P Fox; J W Gerrard; H G Dunn; D S Herbst
Journal:  Am J Med Genet       Date:  1980

4.  Replication status of the fragile X chromosome, fra(X)(q27), in three heterozygous females.

Authors:  R T Howell; A McDermott
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

5.  Additional evidence for fragile X activity in heterozygous carriers.

Authors:  I A Uchida; V C Freeman; H Jamro; M W Partington; H C Soltan
Journal:  Am J Hum Genet       Date:  1983-09       Impact factor: 11.025

6.  Inactivation pattern of the fragile X in heterozygous carriers.

Authors:  J P Fryns; A Kleczkowska; E Kubień; P Petit; H Van den Berghe
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

7.  Carrier detection and X-inactivation studies in the fragile X syndrome. Cytogenetic studies in 63 obligate and potential carriers of the fragile X.

Authors:  K B Nielsen; N Tommerup; H Poulsen; P Jacobsen; B Beck; M Mikkelsen
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

8.  Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells.

Authors:  B R Migeon; H W Moser; A B Moser; J Axelman; D Sillence; R A Norum
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  Activity of the fragile X in heterozygous carriers.

Authors:  I A Uchida; E M Joyce
Journal:  Am J Hum Genet       Date:  1982-03       Impact factor: 11.025

10.  Cytologic evidence for three human X-chromosomal segments escaping inactivation.

Authors:  W Schempp; B Meer
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

View more
  2 in total

1.  Selection in blood cells from female carriers of the fragile X syndrome: inverse correlation between age and proportion of active X chromosomes carrying the full mutation.

Authors:  F Rousseau; D Heitz; I Oberlé; J L Mandel
Journal:  J Med Genet       Date:  1991-12       Impact factor: 6.318

2.  A multicenter study on genotype-phenotype correlations in the fragile X syndrome, using direct diagnosis with probe StB12.3: the first 2,253 cases.

Authors:  F Rousseau; D Heitz; J Tarleton; J MacPherson; H Malmgren; N Dahl; A Barnicoat; C Mathew; E Mornet; I Tejada
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.